publication . Article . 2017

use of parecoxib by continuous subcutaneous infusion for cancer pain in a hospice population

Armstrong, Peter; Wilkinson, Pauline; McCorry, Noleen;
Open Access
  • Published: 01 Sep 2017 Journal: BMJ Supportive & Palliative Care, volume 8, pages 25-29 (issn: 2045-435X, eissn: 2045-4368, Copyright policy)
  • Publisher: BMJ
  • Country: Bangladesh
<jats:sec><jats:title>Objectives</jats:title><jats:p>To characterise the use of the parenteral non-steroidal anti-inflammatory drug parecoxib when given by continuous subcutaneous infusion (CSCI) in a hospice population. Clinical experience suggests parecoxib CSCI may be of benefit in this population, but empirical evidence in relation to its safety and efficacy is lacking.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Retrospective chart review of patients with a cancer diagnosis receiving parecoxib CSCI from 2008 to 2013 at the Marie Curie Hospice, Belfast. Data were collected on treatment regime, tolerability and, in patients receiving ...
free text keywords: Medicine (miscellaneous), Oncology(nursing), Medical–Surgical, General Medicine, Tolerability, Cancer pain, Parecoxib, medicine.drug, medicine, Anesthesia, Retrospective cohort study, Opioid, Adverse effect, business.industry, business, Oral administration, Population, education.field_of_study, education, Short Report, 1506, cancer, pain, symptoms and symptom management
Related Organizations
22 references, page 1 of 2

1 World Health Organisation. WHO’s cancer pain ladder for adults. 1986 (accessed Jan 2017).

2 García Rodríguez LA, Barreales Tolosa L Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology 2007;132:498–506. 10.1053/j.gastro.2006.12.007 17258728 [OpenAIRE] [PubMed] [DOI]

3 Pfizer Limited 2015, January 2-last update, Summary of Product Characteristics. Dynastat 40mg powder for solution for injection. (accessed Jan 2017).

4 Kenner DJ, Bhagat S, Fullerton SL Daily subcutaneous parecoxib injection for cancer pain: an open label pilot study. J Palliat Med 2015;18:366–72. 10.1089/jpm.2014.0249 25695199 [OpenAIRE] [PubMed] [DOI]

5 De Conno F, Zecca E, Martini C, et al Tolerability of ketorolac administered via continuous subcutaneous infusion for cancer pain: a preliminary report. J Pain Symptom Manage 1994;9:119–21. 10.1016/0885-3924(94)90164-3 8021534 [OpenAIRE] [PubMed] [DOI]

6 Blackwell N, Bangham L, Hughes M, et al Subcutaneous ketorolac--a new development in pain control. Palliat Med 1993;7:63–5. 10.1177/026921639300700110 8287202 [OpenAIRE] [PubMed] [DOI]

7 Myers KG, Trotman IF Use of ketorolac by continuous subcutaneous infusion for the control of cancer-related pain. Postgrad Med J 1994;70:359–62. 10.1136/pgmj.70.823.359 8016008 [OpenAIRE] [PubMed] [DOI]

8 Hall E Subcutaneous diclofenac: an effective alternative?Palliat Med 1993;7:339–40.

9 Tang J, Li S, White PF, et al Effect of parecoxib, a novel intravenous cyclooxygenase type-2 inhibitor, on the postoperative opioid requirement and quality of pain control. Anesthesiology 2002;96:1305–9. 10.1097/00000542-200206000-00007 12170040 [OpenAIRE] [PubMed] [DOI]

10 Alkhenizan A, Librach L, Beyene J NSAIDs: are they effective in treating cancer pain?Eur J Palliat Care 2004;11:5–8.

11 Mitchell K, Pickard J, Herbert A, et al Incidence and causes for syringe driver site reactions in palliative care: A prospective hospice-based study. Palliat Med 2012;26:979–85. 10.1177/0269216311428096 22084491 [OpenAIRE] [PubMed] [DOI]

12 Dickman A, Schneider J The syringe driver: continuous subcutaneous infusions in palliative care. 2nd edition Oxford: Oxford University Press, 2011.

13 Hawkins C, Hanks GW The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature. J Pain Symptom Manage 2000;20:140–51. 10.1016/S0885-3924(00)00175-5 10989252 [PubMed] [DOI]

14 Clive DM, Stoff JS Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984;310:563–72. 10.1056/NEJM198403013100905 6363936 [PubMed] [DOI]

15 British Medical Association and Royal Pharmaceutical Society. British national formulary. 72nd ed London: BMJ Group and Pharmaceutical Press, 2016.

22 references, page 1 of 2
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue